Jagsonpal Pharmaceuticals Management
Management criteria checks 0/4
Jagsonpal Pharmaceuticals' CEO is Manish Gupta, appointed in Jul 2022, has a tenure of 1.83 years. total yearly compensation is ₹10.59M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth ₹151.99M. The average tenure of the management team and the board of directors is 1.3 years and 1.9 years respectively.
Key information
Manish Gupta
Chief executive officer
₹10.6m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 1.8yrs |
| CEO ownership | 1.6% |
| Management average tenure | 1.3yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹245m |
| Sep 30 2023 | n/a | n/a | ₹283m |
| Jun 30 2023 | n/a | n/a | ₹313m |
| Mar 31 2023 | ₹11m | ₹11m | ₹267m |
Compensation vs Market: Manish's total compensation ($USD127.03K) is above average for companies of similar size in the Indian market ($USD39.49K).
Compensation vs Earnings: Insufficient data to compare Manish's compensation with company performance.
CEO
Manish Gupta (56 yo)
1.8yrs
Tenure
₹10,590,000
Compensation
Mr. Manish Gupta serves as Operating Partner at Convergent Finance LLP since joining the firm in July 2022. At Convergent, he helps identify and diligence investment opportunities. He is the former CEO and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 1.8yrs | ₹10.59m | 1.61% ₹ 152.0m | |
| Company Secretary & Compliance Officer | 1.3yrs | ₹100.00k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Assistant General Manager of Human Resources | no data | no data | no data |
1.3yrs
Average Tenure
Experienced Management: JAGSNPHARM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 1.8yrs | ₹10.59m | 1.61% ₹ 152.0m | |
| Non-Executive Chairman | 1.9yrs | no data | no data | |
| Chairman Emeritus | no data | ₹6.81m | 4.58% ₹ 433.0m | |
| Non-Executive Director | 1.9yrs | no data | 0.36% ₹ 34.1m | |
| Independent Director | 1.9yrs | ₹1.00m | no data | |
| Independent Director | 1.9yrs | ₹1.08m | no data | |
| Independent Director | 1.9yrs | ₹950.00k | no data |
1.9yrs
Average Tenure
53yo
Average Age
Experienced Board: JAGSNPHARM's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.